# US 2022/0008495 A1 · Application of phlegmyheatclear in preparation of drug for treatment of acute exacerbation of chronic obstructive pulmonary disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008495 A1
- Document ID: US20220008495A1
- Status: Published application
- Kind: A1
- Application number: 17/160,090
- Filed: 2021-01-27
- Published: 2022-01-13
- Earliest claimed: 2020-07-07
- Assignees: Shanghai Kaibao Pharmaceutical Co., Ltd.
- Applicants: Shanghai Kaibao Pharmaceutical Co., Ltd.
- Inventors: Xiaoli Zhang; Jingwei Mu; Shaoyong Liu; Xuehang Du
- Web page: https://patentgrep.com/patent/US20220008495A1

## CPC

- A61K 36/539: Scutellaria (skullcap)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 35/413: Gall bladder; Bile
- A61K 36/355: Lonicera (honeysuckle)
- A61K 36/634: Forsythia
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

## Claims

### Claim 1

An application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

### Claim 2 (depends on 1)

The application of claim 1, wherein the phlegmyheatclear is composed of scutellaria baicalensis, bear gall powder, cornu gorais, honeysuckle flowers and fructus forsythia.

### Claim 3 (depends on 1)

The application of claim 1, wherein the drug further comprises pharmaceutically acceptable excipients.

### Claim 4 (depends on 1)

The application of claim 1, wherein a dosage form of the drug is an oral dosage form or a non-oral dosage form.

### Claim 5 (depends on 4)

The application of claim 4, wherein the oral dosage form comprises tablet, powder, granule, capsule, emulsion, syrup or spray.

### Claim 6 (depends on 4)

The application of claim 4, wherein the non-oral dosage form is an injection.
